Notably, the half-maximal inhibitory concentration (IC50) of commonly used chemotherapeutic drugs, such as lapatinib and mitomycin, was inversely associated with TRAF3IP3 expression in HCC patients. TRAF3IP3 may be as a novel and promising biomarker for prognosis prediction and immunological evaluation of HCC.

6 days ago

Journal

CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)

lapatinib • mitomycin

11d

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) (clinicaltrials.gov)

P3, N=176, Recruiting, University of Southampton | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Dec 2024

11 days ago

Enrollment open • Trial initiation date • Head-to-Head

mitomycin

24d

CD8RGs play an important role in regulating the TME of PAAD. Five hub genes-BCL11A, KLK11, GNG7, PHOSPHO1, and VCAM1-are closely associated with the prognosis of PAAD patients, providing new references for the exploration of biomarkers. Furthermore, our findings offer novel insights for clinical decision-making.

24 days ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • VCAM1 (Vascular Cell Adhesion Molecule 1) • BCL11A (BAF Chromatin Remodeling Complex Subunit BCL11A)

cisplatin • Gilotrif (afatinib) • Ibrance (palbociclib) • gefitinib • paclitaxel • sunitinib • Inlyta (axitinib) • MK-2206 • mitomycin

27d

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) (clinicaltrials.gov)

P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Nov 2031

27 days ago

Trial completion date • Combination therapy

Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • mitomycin

Fanconi Anemia: Challenges in Diagnosis and Management-A Case Series Report. (PubMed, Clin Case Rep)

Interestingly, both patients had negative results on the initial chromosomal breakage test with mitomycin C, a commonly used diagnostic tool for FA...Molecular genetic testing, such as WES, can provide a definitive diagnosis and guide appropriate management strategies. Early and accurate diagnosis is crucial for improving outcomes in individuals with this potentially fatal illness, as promising advancements in treatments such as hematopoietic stem cell transplantation and gene therapy offer hope for addressing FA.

1 month ago

Journal

FANCD2 (FA Complementation Group D2)

mitomycin

MMC: Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery (clinicaltrials.gov)

P3, N=144, Not yet recruiting, St. Joseph's Healthcare Hamilton

1 month ago

New P3 trial • Surgery

mitomycin

2ms

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) (clinicaltrials.gov)

P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2029 --> Jan 2027

2 months ago

Enrollment closed • Trial primary completion date • Combination therapy

Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • mitomycin

2ms

HIPEC for Peritoneal Carcinomatosis (clinicaltrials.gov)

P2, N=51, Completed, Albert Einstein College of Medicine | Trial completion date: Nov 2020 --> Aug 2024

2 months ago

Trial completion date

mitomycin

2ms

The m5C/m6A/m7G-related non-apoptotic regulatory cell death genes for the prediction of the prognosis and immune infiltration status in hepatocellular carcinoma. (PubMed, Transl Cancer Res)

High-risk patients were more responsive to cisplatin, doxorubicin, and mitomycin C, while low-risk patients were more sensitive to erlotinib. We have developed a prognostic model with m5C/m6A/m7G-related NARCD genes to predict the prognosis of HCC patients. This model can offer insights into the effectiveness of immunotherapy and chemotherapy for HCC patients.

2 months ago

Journal

MIF (Macrophage Migration Inhibitory Factor)

cisplatin • erlotinib • doxorubicin hydrochloride • mitomycin

2ms

Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC) (clinicaltrials.gov)

P4, N=216, Recruiting, Hospital Universitario de Fuenlabrada | Trial completion date: Jan 2027 --> Oct 2029 | Trial primary completion date: Jan 2027 --> Oct 2029

2 months ago

Trial completion date • Trial primary completion date

mitomycin

3ms

Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines. (PubMed, Int J Mol Sci)

Drug screening using mitomycin-C (MMC), 5-fluorouricil (5-FU), and 6-Diazo-5-oxo-L-norleucine (DON) were performed...Ocular adnexal SebCA cell lines can be established using conditional reprogramming cell conditions, and our three new models are useful for testing therapies and interrogating the functional role of MYC and other possible molecular drivers. Current topical chemotherapies promote both apoptosis and differentiation in SebCA cells, and these tumors appear sensitive to inhibition or MYC-associated metabolic changes.

3 months ago

Preclinical • Journal

PLIN2 (Perilipin)

5-fluorouracil • mitomycin

4ms

CRC patients with high-risk score more sensitive to docetaxel and rapamycin but resistance to gemcitabine and mitomycin. In the study, a PRGs-based prognostic model and a predictive model were constructed. These models are effective and robust in prediction the 1-, 3-, and 5-year survival of CRC patients.

4 months ago

Journal • Gene Signature • IO biomarker

TMB (Tumor Mutational Burden) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • ICOS (Inducible T Cell Costimulator) • TNFRSF4 (TNF Receptor Superfamily Member 4) • HHLA2 (HERV-H LTR-Associating 2) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand) • CD48 (CD48 Molecule) • AGRN (Agrin) • CD200R1 (CD200 Receptor 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)

gemcitabine • docetaxel • sirolimus • mitomycin

4ms

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology (clinicaltrials.gov)

P2, N=27, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2027 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Apr 2024 | Active, not recruiting --> Completed

4 months ago

Trial completion • Trial completion date • Trial primary completion date • Cytology

HER-2 (Human epidermal growth factor receptor 2)

cisplatin • mitomycin

4ms

CANAL-IMRT-01: Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life (clinicaltrials.gov)

P2, N=71, Active, not recruiting, Centre Francois Baclesse | Trial completion date: Dec 2023 --> Dec 2024

4 months ago

Trial completion date • HEOR • Combination therapy • Metastases

5-fluorouracil • mitomycin

5ms

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer (clinicaltrials.gov)

P2, N=21, Recruiting, University of Chicago | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026

5 months ago

Trial completion date • Trial primary completion date • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1)

cisplatin • mitomycin

5ms

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (clinicaltrials.gov)

P2, N=48, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2024 --> Jun 2025

5 months ago

Trial completion date

mitomycin • Neulasta (pegfilgrastim)

5ms

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) (clinicaltrials.gov)

P3, N=176, Not yet recruiting, University of Southampton

5 months ago

New P3 trial • Head-to-Head

mitomycin

5ms

Primary Conjunctival Basal Cell Carcinoma Mimicking an Ocular Surface Squamous Neoplasia in a Young Adult Filipino: A Case Report and Literature Review. (PubMed, Case Rep Ophthalmol Med)

Four cycles of mitomycin C (0.02%) were administered as chemoadjuvant therapy...In most cases, wide surgical excision is sufficient. In addition, adjuvant therapies may be beneficial in preventing tumor recurrence.

5 months ago

Review • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CEACAM5 (CEA Cell Adhesion Molecule 5) • MME (Membrane Metalloendopeptidase)

mitomycin

5ms

Toxicity and efficacy of type I interferons on the ocular surface: in vitro, animal, and clinical studies. (PubMed, Ocul Surf)

Although type I IFNs cause direct toxicity on corneal cells, they do not induce significant side effects on the healthy ocular surface. Considering its therapeutic and preventive effects, topical type I IFN is safe and effective for treating ocular surface tumors. The potential for ocular side effects should be considered in eyes with identified risk factors.

5 months ago

Preclinical • Journal • IO biomarker

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD40 (CD40 Molecule) • IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)

mitomycin

6ms

Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. (PubMed, J Transl Med)

BRAF mutations were frequently detected and were associated with particularly poor survival in this cohort, possibly related to ligand-dependent Wnt activation and altered drug transport and metabolism that could confer resistance to MMC and irinotecan. Drugs that target ligand-dependent Wnt activation or the BTN immune checkpoints could represent two novel therapy approaches.

6 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)

irinotecan • mitomycin

6ms

Homozygous Variant of FANCM of the Fanconi Anemia Pathway Causes Premature Ovarian Insufficiency: Investigation of the Pathogenic Mechanism (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban)

Mitomycin C was used to induce ICLs damage in vitro in both the EGFP FANCM-WT group and the EGFP FANCM-MUT group, which was followed by verification of its effect on ICLs damage repair using γ-H2AX antibody...Consequently, the localization of the FA core complex on chromatin is disrupted, impeding the normal activation of the FA pathway and reducing the cell's ability to repair damaged ICLs. By disrupting the rapid proliferation and meiotic division processes of primordial germ cells, the reserve of oocytes is depleted, thereby triggering premature ovarian insufficiency in females.

6 months ago

Journal

FANCA (FA Complementation Group A) • FANCM (FA Complementation Group M)

mitomycin

6ms

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer (clinicaltrials.gov)

P3, N=500, Active, not recruiting, Nottingham University Hospitals NHS Trust

6 months ago

New P3 trial

mitomycin

7ms

Role of the CTCF Binding Site in Human T-Cell Leukemia Virus-1 Pathogenesis. (PubMed, bioRxiv)

Hu-mice were infected with mitomycin treated or irradiated HTLV-1 producing cell lines...We found that this mutation slowed virus spread and attenuated the development of disease. Gene expression studies demonstrated a dynamic role of CTCF in regulating viral gene expression and T lymphocyte activation.

7 months ago

Journal

CD4 (CD4 Molecule)

mitomycin

7ms

Postoperative hyphema due to persistent tunica vasculosa lentis in glaucoma associated with neurofibromatosis-a case report. (PubMed, J AAPOS)

Uneventful combined trabeculotomy-trabeculectomy with mitomycin C was performed...Viscotamponade was performed, and the corneal wounds were closed, with the ocular tension slightly elevated. Bleeding did not recur for the following 5 months, and IOP was controlled until final follow-up.

7 months ago

Observational data • Retrospective data • Review • Journal

NF1 (Neurofibromin 1)

mitomycin

7ms

Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan. (PubMed, Int J Clin Oncol)

The comparative etiology, clinical outcomes, and prognostic factors of CCRT observed in Japanese patients with locoregional ASCC were consistent with western data.

7 months ago

Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

5-fluorouracil • mitomycin

7ms

THOR-2: A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)

P2, N=107, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2024 --> Jul 2024

7 months ago

Trial primary completion date

FGFR (Fibroblast Growth Factor Receptor)

FGFR mutation • FGFR fusion

gemcitabine • Balversa (erdafitinib) • mitomycin

7ms

Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Macrophage Polarization-Related Genes. (PubMed, J Hepatocell Carcinoma)

Patients in the high-risk group exhibited increased sensitivity to mitomycin C, cisplatin, gemcitabine, rapamycin, and paclitaxel, while those in the low-risk group showed heightened sensitivity to doxorubicin. The MP-related prognostic model comprising six MPRGs can effectively predict HCC prognosis, infer invasiveness, and guide drug therapy. SCN4A is identified as a suppressor gene in HCC.

7 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • CD163 (CD163 Molecule) • EBF3 (EBF Transcription Factor 3)

cisplatin • gemcitabine • paclitaxel • doxorubicin hydrochloride • sirolimus • mitomycin

8ms

RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer. (PubMed, Front Oncol)

In cell lines, reduction of RFWD3 expression led to increased sensitivity to interstrand crosslinking (ICL) inducing agents mitomycin C and carboplatin. In tumours, low RFWD3 expression was associated with increased tumour mutational burden, and complete response to platinum chemotherapy. RFWD3 expression varies in HGSOCs, which can lead to functional effects at both the cellular and tumour levels.

8 months ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden)

carboplatin • mitomycin

8ms

Enhancing the Efficacy of HIPEC Through Bromelain: A Preclinical Investigation in Appendiceal Cancer. (PubMed, Ann Surg Oncol)

Bromelain demonstrates cytotoxicity and mucolytic activity against appendiceal cancer organoids. As a pretreatment agent, it potentiates the cytotoxicity of multiple HIPEC regimens, potentially mediated through programmed cell death and autophagy.

8 months ago

Preclinical • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • MUC2 (Mucin 2) • ATG7 (Autophagy Related 7) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)

cisplatin • mitomycin

8ms

Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside. (PubMed, J Exp Clin Cancer Res)

Our study suggests that PDOs could be a reliable in vitro model to evaluate HIPEC schemes at individual-patient level and to develop more effective treatment strategies for CRCPM.

8 months ago

Journal

CASP3 (Caspase 3)

cisplatin • doxorubicin hydrochloride • oxaliplatin • mitomycin

8ms

IMGeS: The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy (clinicaltrials.gov)

P2, N=82, Recruiting, National Cancer Center, Korea

8 months ago

New P2 trial

gemcitabine • mitomycin

8ms

SunRISe-5: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (clinicaltrials.gov)

P3, N=250, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

8 months ago

Enrollment open

mitomycin • GemRIS (gemcitabine-releasing intravesical system)

8ms

Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial. (ASCO 2024)

We performed a correlative study to help determine if using SigNatera ctDNA would be a predictive and prognostic biomarker of recurrent cancer in patients who underwent CRS-HIPEC on a Phase II Randomized Trial Comparing Morbidity and Mortality of CRS-HIPEC using Mitomycin-C versus Melphalan for Colorectal and Appendiceal Peritoneal Carcinomatosis. The unexpected numerically favorable DFS in the pre-op ctDNA(+) group, in comparison to the pre-op ctDNA(-) group, challenges the utility of preop ctDNA status in guiding CRS + HIPEC decision-making. Though limited by small sample size, this finding may be likely due to the impact of post-op therapy which notably converted 10 preop ctDNA(+) pts to post-op ctDNA(-) status. Our findings warrant validation in a larger study to unravel the multifaceted factors influencing ctDNA's prognostic value.

8 months ago

P2 data • Clinical

Signatera™

mitomycin • melphalan

8ms

Surgical resection combined with intraperitoneal chemotherapy (CT) is the best treatment for selected patients with Peritoneal Metastases from colon cancer. However, the real role of intraperitoneal CT as a necessary component of this treatment is unknown, despite its proven experimental basis. The main objective of this study is to clarify it, so one group of patients will be treated with surgery + intraperitoneal CT and the other with surgery alone. La resección quirúrgica combinada con quimioterapia (QT) intraperitoneal es el mejor tratamiento para pacientes seleccionados con metástasis peritoneales de cáncer de colon. Sin embargo, se desconoce el papel real de la QT intraperitoneal como componente necesario de este tratamiento, a pesar de su probada base experimental. El objetivo principal de este estudio es aclararlo, por lo que un grupo de pacientes será tratado con cirugía + QT intraperitoneal y el otro solo con cirugía. (clinicaltrialsregister.eu)

P4, N=216, Ongoing, Hospital Universitario de Fuenlabrada

8 months ago

New P4 trial • Surgery

MSI (Microsatellite instability)

mitomycin

8ms

Mitomycin C and Its Analog Trigger Cytotoxicity in MCF-7 and K562 cancer cells through the regulation of RAS and MAPK/ERK pathways. (PubMed, Chem Biol Interact)

Furthermore, treatment of MCF-7 and K562 cell lines with oligonucleotides containing the interstrand crosslinks (ICLs) formed by MC or DMC shows that both ICLs had a stronger effect on the downregulation of RAS protein expression in mutant TP53 K562 cells. We discuss the implication of this regulation of the MAPK/ERK pathway in relation to cellular TP53 status.

8 months ago

Journal

CDKN1A (Cyclin-dependent kinase inhibitor 1A)

TP53 mutation • TP53 expression

mitomycin

9ms

Construction of a Cancer Stem Cell related Histone Acetylation Regulatory Genes Prognostic Model for Hepatocellular Carcinoma via Bioinformatics Analysis: Implications for Tumor Chemotherapy and Immunity. (PubMed, Curr Stem Cell Res Ther)

This study constructed a mRNAsi and HAGs-related prognostic model, which has implications for potential immunotherapy and drug treatment of LIHC.

9 months ago

Journal • Cancer stem • IO biomarker • Epigenetic controller

HDAC1 (Histone Deacetylase 1) • HDAC11 (Histone Deacetylase 11) • HAT1 (Histone Acetyltransferase 1)

Zarnestra (tipifarnib) • mitomycin • bleomycin

9ms

Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 months of disease regression in a patient with breast cancer liver metastases resistant to multiple systemic chemotherapies. (PubMed, Int Cancer Conf J)

A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38 months; letrozole, nivolumab/fulvestrant, eribulin, gemcitabine/vinorelbine, high-dose toremifene/abemaciclib, and capecitabine for 21 months in total). However, owing to its adverse effects and the continued progression of the LMs, systemic therapy was switched to HAIC (40 mg/body epirubicin on day 1, 4 mg/body mitomycin C on days 1 and 15, and 500 mg/body 5-fluorouracil on days 1, 8, and 15; 28-day courses)...Our findings identify a potential window for the use of traditional chemotherapeutic agents such as anthracyclines. Novel strategies to improve drug delivery are warranted in the future.

9 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)

ER positive • HER-2 negative • EGFR positive

Opdivo (nivolumab) • Avastin (bevacizumab) • gemcitabine • paclitaxel • 5-fluorouracil • capecitabine • Verzenio (abemaciclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • epirubicin • vinorelbine tartrate • mitomycin

10ms

P2, N=108, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2025 --> Mar 2025

10 months ago

Trial completion date

FGFR (Fibroblast Growth Factor Receptor)

FGFR mutation • FGFR fusion

gemcitabine • Balversa (erdafitinib) • mitomycin

10ms

UF-GU-001: Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma (clinicaltrials.gov)

P2, N=29, Completed, University of Florida | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Dec 2023

10 months ago

Trial completion • Trial completion date

mitomycin

10ms

Screening of growth inhibitors for epithelial-mesenchymal transition-induced cells by TGF-β from plant-based sources identified the active compound hydroxychavicol from Piper bitle. (PubMed, J Nat Med)

The anti-cancer agents, mitomycin C, cisplatin, and staurosporine, lacked the characteristics as that of nanaomycin K for these four treatment conditions. Furthermore, hydroxychavicol exhibited same activity against SAS cells (human squamous cell carcinoma of the tongue). Thus, we have successfully established a screening method for growth inhibitors of EMT-induced cells and have discovered an inhibitor from plant-based sources.

10 months ago

Journal

TGFB1 (Transforming Growth Factor Beta 1)

cisplatin • mitomycin

10ms

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (clinicaltrials.gov)

P2, N=48, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Jun 2024

10 months ago

Trial completion date

mitomycin • Neulasta (pegfilgrastim)

11ms

The role of URO17Â® in diagnosis and follow up of bladder cancer patients. (PubMed)

URO17Â® has a potential to be a reliable test for diagnosis and follow up of urothelial cancer patients and a screening tool adjunct to flexible cystoscopy.

11 months ago

Journal

URO17™

mitomycin